Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1561 to 1575 of 2186 results for guidelines

  1. Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care (HTG508)

    Evidence-based recommendations on lead-I electrocardiogram (ECG) devices (imPulse, Kardia Mobile, MyDiagnostick and Zenicor-ECG) for detecting symptomatic atrial fibrillation using single time point testing in primary care.

    HealthTech guidance
    Published
    8 May 2019
    View recommendations

    Sections for HTG508

  2. Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)

    Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC deficiency in people 6 years and over.

    Highly specialised technologies guidance
    Published
    6 July 2022
    View recommendations

    Sections for HST21

  3. Etelcalcetide for treating secondary hyperparathyroidism (TA448)

    Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.

    Technology appraisal guidance
    Published
    28 June 2017
    View recommendations

    Sections for TA448

  4. Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)

    Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cancer after chemotherapy in adults.

    Technology appraisal guidance
    Published
    29 July 2024
    View recommendations

    Sections for TA992

  5. Guide to the processes of technology appraisal (PMG19)

    This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes

  6. What is the relative effectiveness and cost effectiveness of different oral fluids and different oral fluid regimens, both with and without oral N-acetylcysteine, at preventing contrast-induced acute kidney injury?

    factors were taken from recommendation 1.1.6 (developed as part of the 2013 guideline) apart from the level of eGFR which was based on...

    Research recommendation
    Published
    10 February 2020

  7. What is the clinical and cost effectiveness of opioids for the management of acute sciatica?

    prescribed for sciatica. They noted that advice is already included in this guideline for the use of paracetamol for people with low...

    Research recommendation
    Published
    22 January 2021

  8. What is the clinical and cost effectiveness of antidepressants for the management of sciatica?

    prescribed for sciatica. They noted that advice is already included in this guideline for the use of paracetamol for people with low...

    Research recommendation
    Published
    26 October 2020

  9. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)

    NICE has developed a medtech innovation briefing (MIB) on CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic .

    Medtech innovation briefing
    Published
    10 July 2020

  10. Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

    Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.

    Technology appraisal guidance
    Last updated
    7 February 2018
    View recommendations

    Sections for TA161

  11. Hyperglycaemia in acute coronary syndromes: management (CG130)

    This guideline has been replaced by NICE guideline NG185.

    Withdrawn guideline

  12. Immunisations: reducing differences in uptake in under 19s (PH21)

    This guideline has been replaced by NICE guideline NG218.

    Withdrawn guideline

  13. Postnatal care up to 8 weeks after birth (CG37)

    This guideline has been replaced by NICE guideline NG194.

    Withdrawn guideline

  14. Chronic heart failure: Management of chronic heart failure in adults in primary and secondary care (CG5)

    This guideline has been updated and replaced by NICE guideline CG108.

    Withdrawn guideline

  15. Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): diagnosis and management (CG53)

    This guideline has been updated and replaced by NICE guideline NG206.

    Withdrawn guideline